News
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife.
“I am pleased to welcome Ron to the senior leadership team at T-knife,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Ron is a seasoned executive who has led the legal, compliance and business operations functions at several innovative biotech companies, and additionally has specialized expertise in patent law. As a rapidly growing organization with multiple pipeline programs, his contributions will be instrumental as we pursue our mission of developing best-in-class T-cell receptor (TCR) therapies to transform patient outcomes.”
BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella
— Successful initial treatment of pectus excavatum patient in Australia
— Data published in the European Journal of Plastic Surgery confirms Bellaseno’s novel approach in soft tissue engineering
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella® in the European Journal of Plastic Surgery. In the trial, a 22-year old patient with severe pectus excavatum received a custom-made, 3D-printed, biodegradable and highly porous Senella® scaffold filled with autologous fat graft to correct her chest deformation.
ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer
– Company adds significant immunotherapy development expertise to its management team
– Clinical trial of lead compound IOS-1002 to start in 2022
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Steve Coats, PhD, has been appointed as Chief Development Officer.
Mr. Coats brings more than 25 years of industry expertise with a focus on antibody drug development that includes scientific excellence coupled with executive-level success, driving strategic initiatives and innovations in drug development. Read more…